"Buy and hold" is a simple strategy for investors, but it can be a hard one to stick to in actual practice. That's because ...

AbbVie’s stock is having a glow-up, climbing 16.1% in 2025, leaving the industry and S&P 500 behind in the dust. The company deftly pivoted after Humira’s fall from patent grace by betting big on ...